Other News To Note

 Optimer Pharmaceuticals Canada Inc., of Toronto, a unit of Optimer Pharmaceuticals Inc., said Canadian regulators approved Dificid (fidaxomicin) for the treatment of Clostridium difficile infection in patients 18 and older. The product, a macrocycle antibiotic, gained approval in the U.S. last year.